Journal ArticleDOI
Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study
Tai-Shuan Lai,Mei Hsuan Lee,Hwai I. Yang,San Lin You,Sheng Nan Lu,Li Yu Wang,Yong Yuan,Gilbert L'Italien,Kuo-Liong Chien,Chien-Jen Chen +9 more
Reads0
Chats0
TLDR
It is revealed that chronic HCV infection is associated with an increased risk of developing ESRD and suggests that elevated serum levels of HCV RNA (>167,000 IU/mL) and HCV genotype 1 are strong predictors of ESRd, indicating clinical implications for the management of chronicHCV.About:
This article is published in Hepatology.The article was published on 2017-09-01. It has received 54 citations till now. The article focuses on the topics: End stage renal disease & Viral load.read more
Citations
More filters
Journal ArticleDOI
EASL Recommendations on Treatment of Hepatitis C
Jean-Michel Pawlotsky,Alessio Aghemo,Geoffrey Dusheiko,Xavier Forns,Massimo Puoti,Christophe Sarrazin +5 more
TL;DR: The optimal management of patients with acute and chronic HCV infections in 2018 and onwards is described, as well as developments in diagnostic procedures and improvements in therapy and prevention.
Journal ArticleDOI
EASL recommendations on treatment of hepatitis C: Final update of the series ☆
Jean-Michel Pawlotsky,Francesco Negro,Alessio Aghemo,Marina Berenguer,Olav Dalgard,Geoffrey Dusheiko,Fiona Marra,Massimo Puoti,Heiner Wedemeyer +8 more
TL;DR: These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.
Journal ArticleDOI
Association between hepatitis B virus and chronic kidney disease: a systematic review and meta-analysis.
TL;DR: HBV infection is possibly associated with a risk of developing reduced glomerular filtration rate in the general population; no link between HBV sero-positive status and frequency of chronic kidney disease or proteinuria was noted in cross-sectional surveys.
Journal ArticleDOI
2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations.
Ming-Lung Yu,Pei-Jer Chen,Chia-Yen Dai,Tsung Hui Hu,Chung Feng Huang,Yi Hsiang Huang,Chao-Hung Hung,Chun-Yen Lin,Chen-Hua Liu,Chun-Jen Liu,Cheng Yuan Peng,Han-Chieh Lin,Jia-Horng Kao,Wan-Long Chuang +13 more
TL;DR: The Taiwan Association for the Study of the Liver (TASL) proposes the treatment recommendations for the special population in order to serve as guidance to optimizing the outcome in the direct-acting antiviral (DAA) era.
Journal ArticleDOI
Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes.
Jia Li,Stuart C. Gordon,Loralee B Rupp,Talan Zhang,Sheri Trudeau,Scott D. Holmberg,Anne C. Moorman,Philip R. Spradling,Eyasu H. Teshale,Joseph A. Boscarino,Mark A Schmidt,Yihe G. Daida,Mei Lu +12 more
TL;DR: The role of hepatitis C (HCV) eradication on the long‐term complications of type 2 diabetes mellitus remains incompletely studied.
References
More filters
Journal ArticleDOI
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
Journal ArticleDOI
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
Chien-Jen Chen,Hwai I. Yang,Jun Su,C.-L. Jen,San Lin You,Sheng-Nan Lu,Guan-Tarn Huang,Uchenna H. Iloeje +7 more
TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.
Journal ArticleDOI
Global epidemiology and genotype distribution of the hepatitis C virus infection
TL;DR: The total number of HCV infections reported here are lower than previous estimates, and the exclusion of data from earlier studies conducted at the peak of the HCV epidemic, along with adjustments for reduced prevalence among children, are likely contributors.
Journal ArticleDOI
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam H. Afdhal,K. Rajender Reddy,David R. Nelson,Eric Lawitz,Stuart C. Gordon,Eugene R. Schiff,Ronald Nahass,Reem Ghalib,Norman Gitlin,Robert Herring,Jacob Lalezari,Ziad Younes,Paul J. Pockros,Adrian M. Di Bisceglie,Sanjeev Arora,G. Mani Subramanian,Yanni Zhu,Hadas Dvory-Sobol,Jenny C. Yang,Phillip S. Pang,William T. Symonds,John G. McHutchison,Andrew J. Muir,Mark S. Sulkowski,Paul Y. Kwo +24 more
TL;DR: Treatment with a once-daily, single-tablet regimen of ledipasvir and sofosbuvir resulted in high rates of sustained virologic response among patients with HCV genotype 1 infection who had not had a sustained virologyic response to prior interferon-based treatment.
Related Papers (5)
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
Edward Gane,Eric Lawitz,David Pugatch,Georgios Papatheodoridis,Norbert Bräu,Norbert Bräu,Ashley Brown,Stanislas Pol,Vincent Leroy,Marcello Persico,Christophe Moreno,Massimo Colombo,Massimo Colombo,Eric M. Yoshida,David R. Nelson,Christine Collins,Yang Lei,Matthew P. Kosloski,Federico J. Mensa +18 more
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
David Roth,David R. Nelson,Annette Bruchfeld,AnnMarie Liapakis,Marcelo Silva,Howard Paul Monsour,Paul J. Martin,Stanislas Pol,Maria Carlota Londoño,Tarek Hassanein,Philippe J. Zamor,Eli Zuckerman,Shuyan Wan,Beth Jackson,Bach-Yen Nguyen,Michael N. Robertson,Eliav Barr,Janice Wahl,Wayne Greaves +18 more